Rossana Intini
About
Rossana Intini is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Rossana Intini has authored 29 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rossana Intini's work include Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (15 papers) and Cancer Genomics and Diagnostics (8 papers). Rossana Intini is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (15 papers) and Cancer Genomics and Diagnostics (8 papers). Rossana Intini collaborates with scholars based in Italy, United States and Spain. Rossana Intini's co-authors include Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Matteo Fassan, Filippo Pietrantonio, Marta Schirripa, Alessandra Anna Prete, Francesca Corti, Margherita Ambrosini and Chiara Cremolini and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.
In The Last Decade
Rossana Intini
27 papers receiving 304 citations
Peers
Rossana Intini
Yueyun Chen China
Miaomiao Gou China
Nebojša Manojlović Serbia
Seung Tae Kim South Korea
Raphaël Colle France
Burçin Baran Türkiye
Helena Taflin Sweden
Xiaohong Yan United States
T.W. Kim South Korea
Van K. Morris United States
Citations per year, relative to Rossana Intini Rossana Intini (= 1×)
peers
Yueyun Chen
Countries citing papers authored by Rossana Intini
Since
Specialization
Citations
This map shows the geographic impact of Rossana Intini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rossana Intini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rossana Intini more than expected).
Fields of papers citing papers by Rossana Intini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rossana Intini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rossana Intini. The network helps show where Rossana Intini may publish in the future.
Co-authorship network of co-authors of Rossana Intini
This figure shows the co-authorship network connecting the top 25 collaborators of Rossana Intini. A scholar is included among the top collaborators of Rossana Intini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rossana Intini. Rossana Intini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Moretto, Roberto, Daniele Rossini, Carlotta Antoniotti, et al.. (2025). The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European Journal of Cancer. 222. 115470–115470.
2.
Germani, Marco Maria, Carlotta Antoniotti, Lisa Salvatore, et al.. (2025). Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy. Therapeutic Advances in Medical Oncology. 17. 12744711–12744711.
3.
Angerilli, Valentina, Rossana Intini, Francesca Bergamo, et al.. (2024). Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper. Critical Reviews in Oncology/Hematology. 206. 104574–104574.
4.
Germani, Marco Maria, Rossana Intini, Maria Bensi, et al.. (2024). Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. ESMO Open. 9(4). 102996–102996.
5.
Moretto, Roberto, Sabina Murgioni, Marco Maria Germani, et al.. (2024). KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration. JCO Precision Oncology. 8(8). e2400329–e2400329.
6.
Prete, Alessandra Anna, Valentina Angerilli, Francesca Bergamo, et al.. (2024). HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study. British Journal of Cancer. 130(8). 1316–1323.
7.
Barretta, Francesco, Francesca Corti, Sara Lonardi, et al.. (2023). Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. 11(1). e005493–e005493.
8.
Gallois, Claire, Julien Taı̈eb, Sara Lonardi, et al.. (2023). Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.. Journal of Clinical Oncology. 41(16_suppl). 3570–3570.
9.
Remo, Andrea, Quoc Riccardo Bao, Edoardo D’Angelo, et al.. (2023). Association between Pancreatoblastoma and Familial Adenomatous Polyposis: Review of the Literature with an Additional Case. Genes. 15(1). 44–44.
10.
Manca, Paolo, Francesca Corti, Rossana Intini, et al.. (2023). Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. European Journal of Cancer. 187. 15–24.
11.
Prete, Alessandra Anna, Rossana Intini, Valentina Angerilli, et al.. (2023). Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study.. Journal of Clinical Oncology. 41(4_suppl). 218–218.
12.
Germani, Marco Maria, Maria Bensi, Carlotta Antoniotti, et al.. (2023). P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment. Annals of Oncology. 34. S45–S45.
13.
Cohen, Romain, Sara Lonardi, Francesca Corti, et al.. (2022). Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. European Journal of Cancer. 172. 171–181.
14.
Corti, Francesca, Sara Lonardi, Rossana Intini, et al.. (2021). The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer. 150. 155–167.
15.
Randon, Giovanni, Rossana Intini, Chiara Cremolini, et al.. (2021). Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. European Journal of Cancer. 161. 90–98.
16.
Lonardi, Sara, Filippo Pietrantonio, Alessandra Anna Prete, et al.. (2020). 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment. Annals of Oncology. 31. S412–S412.
17.
Catalano, Vincenzo, Francesca Bergamo, Chiara Cremolini, et al.. (2019). Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. Journal of Cancer Research and Clinical Oncology. 146(2). 493–501.
18.
Battaglin, Francesca, Alberto Puccini, Rossana Intini, et al.. (2018). The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy. 18(3). 251–266.
19.
Rossini, Daniele, Chiara Cremolini, Elena Conca, et al.. (2018). Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. Annals of Oncology. 29. v102–v102.
20.
Catalano, Vincenzo, Francesca Bergamo, Chiara Cremolini, et al.. (2017). Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients. Annals of Oncology. 28. vi3–vi3.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yueyun Chen Breakdown of academic impact, for papers by Miaomiao Gou Breakdown of academic impact, for papers by Nebojša Manojlović Breakdown of academic impact, for papers by Seung Tae Kim Breakdown of academic impact, for papers by Raphaël Colle Breakdown of academic impact, for papers by Burçin Baran Breakdown of academic impact, for papers by Helena Taflin Breakdown of academic impact, for papers by Xiaohong Yan Breakdown of academic impact, for papers by T.W. Kim Breakdown of academic impact, for papers by Van K. Morris